

Original Article

Comparative transcriptome analysis using RNA-Seq screening reveals critical genes and regulatory mechanisms of gastric carcinogenesis involved in *helicobacter pylori* infections and CagA

Yanyan Shi¹, Qiang Li²

¹Peking University Third Hospital, Research Center of Clinical Epidemiology, Beijing 100191, P.R. China; ²The Ministry of Science and Technology (MoST), Exchange, Development & Service Center for Science & Technology Talents, Beijing 100045, P.R. China

Received March 18, 2019; Accepted May 7, 2019; Epub July 15, 2019; Published July 30, 2019

Abstract: Background: *Helicobacter pylori* (*H. pylori*) has been hurred into the spotlight as an important pathogenic factor in the development of gastric cancer. Mechanisms of *H. pylori*, however, need to be clarified. Methods: Gastric cancer AGS cells were infected with CagA⁺ and CagA⁻ *H. pylori* strains at multiplicities of 25:1. Comparative transcriptome analysis using RNA-seq screening was used to identify genes regulated by *H. pylori* and *H. pylori* CagA. These were validated by real-time PCR. Results: A total of 2,181 genes were identified to be significantly differentially-expressed from the three groups. Genes involved in cellular response to stress and cell death were highly enriched under 26695 *H. pylori* infections. Genes involved in mitotic sister chromatid segregation and mitotic cell cycle were enriched, comparing CagA⁺ and CagA⁻ *H. pylori* infections. IL-8, IL-33, TFF1, MUC13, MUC5AC, EGFR, VEGFA, and BCL2L1 genes were verified to be upregulated after *H. pylori* infections. EGFR and VEGFA gene-expression changes induced by *H. pylori* did not depend on CagA. Conclusion: Novel and significant differentially-expressed genes were identified in this study. Present data provides a crucial resource, determining specific responses to *H. pylori* infections or *H. pylori* CagA in gastric cancer cells.

Keywords: *Helicobacter pylori*, CagA, RNA-seq, real-time PCR, gastric cancer

Introduction

Gastric cancer is one of the most common cancer, imposing a considerable health burden all over the world [1]. *Helicobacter pylori* (*H. pylori*) is a pathogen that colonizes mucosal surfaces of the human stomach. Persistent colonization of *H. pylori*, combined with the highly inflammatory response of the host, is a critical factor associated with severe manifestations of gastric disease [2]. Evidence has shown that *H. pylori* infections increase the risk of gastric cancer. The International Agency for Research on Cancer has classified *H. pylori* as a group I carcinogen, causing gastric cancer in humans [3-5].

H. pylori virulence factors play an important role in determining outcomes of gastric diseases [6]. One well-known *H. pylori* virulence factor

that augments cancer risk is CagA. CagA can be translocated into host cells, subsequently interferes with cellular processes [7]. Infections with cagA-positive *H. pylori* strains have been associated with an increased risk of developing gastric cancer. CagA has been designated a bacterial oncoprotein [8]. Numerous studies have been conducted concerning the pathogenicity of *H. pylori* or *H. pylori* CagA [9-11]. However, the mechanisms of *H. pylori* or *H. pylori* CagA on gastric carcinogenesis are complex and remain unclear.

RNA sequencing technology provides researchers with a revolutionary method. It is highly precise, rapid, reproducible, and cost-effective. This technique has been used in comparative transcriptomics, identifying differential-gene expression among various treatment conditions. The present study generated a transcrip-

tome dataset using the IlluminaHiSeq™ 2500 platform, gaining a profile of regulated genes in gastric cells according to *H. pylori* or CagA⁻ *H. pylori* infections. The aim of this study was to highlight the mechanisms of *H. pylori* and *H. pylori* CagA.

H. pylori infected gastric cell culture models are suitable for *in vitro* infections of *H. pylori*. Human-derived AGS gastric epithelial cells are used in *H. pylori* infection cell models *in vitro*. AGS cell line co-culturing with *H. pylori* has been used to investigate the mechanisms of *H. pylori* on gastric carcinogenesis [12, 13]. The present study used the most classic *in vitro* study model to explore the pathogenic mechanisms of *H. pylori* infections.

Materials and methods

H. pylori culturing

H. pylori strains, ATCC 26695 (CagA⁺) and Hp8822 (CagA⁻), were used in this study. *H. pylori* strains were cultured, respectively, on blood agar plates containing 39 g l⁻¹ Columbia solid culture medium (Oxoid), 5% (v/v) sheep's blood (Curtin Matheson, Jessup, MD, USA), antibiotics amphotericin B 4 µg ml⁻¹ (Life Tech, Carlsbad, CA, USA), trimethoprim 4 µg ml⁻¹, and vancomycin 4 µg ml⁻¹. The plates were incubated at 37°C for 3-5 days in a microaerobic environment (5% (v/v) O₂, 10% (v/v) CO₂, and 85% (v/v) N₂). Before harvesting, the *H. pylori* cultures were examined using urease tests and Gram staining. Oxidase tests and catalase tests were also used, ensuring that the strains were not contaminated.

Cell culturing, culture conditions, and co-culture assays

AGS cells were cultured in RPMI1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS) (Hyclone, Logan, UT, USA). AGS cells were cultured at 37°C in a humidified incubator in 5% (v/v) CO₂. After the cultures had been resuscitated on blood agar plates, *H. pylori* 26695 (CagA⁺) and Hp8822 (CagA⁻) were harvested and washed with PBS three times. They were prepared in the cell growth medium and diluted to a final concentration of 1×10⁸ CFU mL⁻¹. AGS cells were plated one day before *H. pylori* treatment. For co-culturing of cells and strains, the cells were rinsed once with PBS

before fresh growth medium was added. Bacterial strains were then added to the cell medium at a multiplicity of infection (MOI) of 50:1 for 24 hours. There were three groups, including negative control cells, as AGS1, *H. pylori* 26695 (CagA⁺) infected cells, as AGS3, and Hp8822 (CagA⁻) infected cells, as AGS4.

RNA isolation, cDNA library preparation, and whole transcript analysis via RNA-sequencing

Total RNA was extracted using TRIzol Reagent (Tiangen, Beijing) and assessed with Agilent 2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA) and QubitFluorometer (Invitrogen). Total RNA samples meeting the following requirements were used in subsequent experiments: 1) RNA integrity number (RIN) > 7.0; 2) 28S:18S ratio > 1.8. RNA-seq libraries were generated and sequenced by CapitalBio Technology (Beijing, China). Triplicate samples of all assays were used to construct an independent library, with the following sequencing and analysis. Next Ultra RNA Library Prep Kit for Illumina (NEB) was used to construct libraries for sequencing. Next Poly(A) mRNA Magnetic Isolation Module kit (NEB) was used to enrich the poly(A) tailed mRNA molecules from 1 µg total RNA. The mRNA was fragmented into ~200 base pair pieces. First-strand cDNA was synthesized from the mRNA fragments reverse transcriptase and random hexamer primers. Second-strand cDNA was then synthesized using DNA polymerase I and RNaseH. The end of the cDNA fragment was subjected to an end repair process, including the addition of a single "A" base, followed by ligation of the adapters. Products were purified and enriched by polymerase chain reaction (PCR), amplifying the library DNA. The final libraries were quantified using the KAPA Library Quantification kit (KAPA Biosystems, South Africa) and an Agilent 2100 Bioanalyzer. After quantitative reverse transcription-polymerase chain reaction (RT-qPCR) validation, the libraries were subjected to paired-end sequencing, with pair end 150-base pair reading lengths on an Illumina Hi-Seqencer (Illumina) [14].

RNA-seq analysis for differentially-expressed genes (DEGs)

The genome of human genome version of hg19 was used as reference. Sequencing quality was assessed with FastQC (Version 0.11.5). Low-quality data was filtered using NGSQC (v0.4).

Clean reads were then aligned to the reference genome using HISAT2 (Johns Hopkins University, USA), with default parameters [15]. Processed reads from each sample were aligned using HISAT2 (Johns Hopkins University, USA) against the reference genome. Gene expression analyses were performed with Cuffquant and Cuffnorm (Cufflinks 2.2.1).

Cuffdiff was used to analyze DEGs between samples. The standardization method of Cuffdiff is geometric, with the per-condition and pooled as the discrete model [16]. Thousands of independent statistical hypothesis testing was conducted on DEGs, separately. *P*-values were then obtained. They were corrected by the FDR method. Corrected *P*-values were calculated by correction with the BH method. *P*-values were used to conduct significance analysis [17]. Parameters for classifying significant DEGs included ≥ 2 -fold differences ($|\log_2 FC| \geq 1$, FC: the fold change of expressions) in the transcript abundance and $P < 0.05$.

Gene ontology (GO) and KEGG enrichment analyses of DEGs

Pearson's correlation coefficient was computed for fragments per kilobase of exon per million fragments mapped (FPKM) and \log_{10} (FPKM) values for genes from each group. DEGs were analyzed using the search tool DAVID (<http://david.abcc.ncifcrf.gov/>) for gene ontology (GO) annotation and enrichment analysis, including three main modules. These included biological process, cellular component, and molecular function. Web-based Kyoto Encyclopedia of Genes and Genomes (KEGG, <http://www.genome.jp/kegg>), BioCyc (<http://biocyc.org/>), Reactome (<http://www.reactome.org/>), and Panther (<http://www.pantherdb.org/>) were used for pathway analysis.

Real-time quantitative PCR

Eight DEGs identified by RNA-seq were validated using real-time PCR. Total RNA was isolated from three groups and was used for real-time quantitative PCR. Real-time quantitative PCR was performed, as described previously [3]. SYBR Green on a Light Cycler 480II Real-time PCR Detection System (Roche) was used. Each real-time PCR procedure was performed in triplicate. Primers included: 18S rRNA: 5'-GTAACCGTGAACCCATT-3' (forward primer) and 5'-

CCATCCAATCGGTAGTAGCG-3' (reverse primer); IL-8: 5'-AAGACATACTCCAAACCTTCCACC-3' (forward primer) and 5'-TTCAAAAACCTTCCACAAACCTCT-3' (reverse primer); IL-33: 5'-GTGACGGTGTGATGGTAAGATG-3' (forward primer) and 5'-CCTGGTCTGGCAGTGGTTTT-3' (reverse primer); TFF1: 5'-AGGCCAGACAGAGACGTGTACAGT-3' (forward primer) and 5'-ACGTCGATGGTATTAGGATAGAAG-3' (reverse primer); MUC13: 5'-TCTGAAATGCGTGCTGATGA-3' (forward primer) and 5'-AGTCATCCGCAGTCTGGTTAC-3' (reverse primer); MUC5AC: 5'-TCACCAACACCAGCAAGAGCC-3' (forward primer) and 5'-GTGACCACCAGAGCCCATCC-3' (reverse primer); EGFR: 5'-CTATCAATCAGCCTCTGAACC-3' (forward primer) and 5'-TAATTTGGTGGCTGCCTTTC-3' (reverse primer); VEGFA: 5'-GGCCAGCACATAGGAGAGAT-3' (forward primer) and 5'-ACGCTCCAGGACTTATACCG-3' (reverse primer); BCL2L1: 5'-CCCTTCAGAATCTTATCTTG-3' (forward primer) and 5'-TG-TAGGAGAGAAAGTCAACC-3' (reverse primer).

Expression levels of selected genes were normalized to that of the 18S rRNA gene, which was used as the internal reference gene. Relative gene expression levels were evaluated using the $2^{-\Delta\Delta Ct}$ method [18].

Results

Overview of RNA-seq results

Exploring the molecular mechanisms of *H. pylori* infections and *H. pylori* CagA in gastric carcinogenesis, this study treated gastric cancer AGS cells with *H. pylori* 26695 (CagA⁺) or Hp8822 (CagA⁻), respectively at a MOI of 25:1 for 24 hours. As described, negative control cells were numbered as AGS1. Cells infected with *H. pylori* 26695 (CagA⁺) were numbered AGS3 and cells infected with Hp8822 (CagA⁻) were numbered as AGS4. Three sequencing libraries were prepared from AGS1, AGS3, and AGS4 samples. They were sequenced with the Illumina HiSeq platform.

Pearson's correlation coefficients were calculated for each of the two groups. Pearson's correlation coefficient for AGS1 and AGS3 was 0.877. For AGS1 and AGS4, Pearson's correlation coefficient was 0.919. For AGS3 and AGS4, Pearson's correlation coefficient was 0.962. Pearson's correlation coefficients of the two groups are shown in a heatmap (**Figure 1A**). It shows that *H. pylori* 26695 (CagA⁺) infections

Helicobacter pylori and gastric carcinogenesis




Figure 1. A. Pearson's correlation coefficients among each two groups are shown in a heatmap. AGS1, negative control AGS cells without *H. pylori* infection; AGS3, AGS cells with *H. pylori* 26695 (*CagA*⁺) infection; AGS4, AGS cells with *CagA*⁻ *H. pylori* infection. B. Differentially-expressed genes were identified in different treatment groups. C. Venn diagrams show overlaps of differentially-expressed genes among the three comparisons. D. Expression levels of dysregulated genes identified by RNA-seq from the three groups (AGS1, AGS3, AGS4) are shown in a heatmap. Red-colored clusters represent the high gene expression quantity, while green-colored clusters represent low gene expression quantity.

(AGS3) produced more changed genes, compared with Hp8822 (*CagA*⁻) infections (AGS4).

Gene expression profile and cluster analysis

Based on deep sequencing of the three libraries used in this study, 1,804 genes were identified to be differentially-expressed between AGS1 and AGS3. Moreover, 1,038 genes were identified between AGS1 and AGS4, while 340 genes were identified between AGS3 and AGS4

(**Figure 1B**). The Venn diagram shows the distribution of expressed genes among the three samples (**Figure 1C**). A total of 2,181 genes were identified to be significantly differentially-expressed from the three groups, in which 20 proteins were common to all three groups. A heatmap was constructed from the data obtained for differentially-expressed genes. Clustering analysis showed that these genes were differentially-expressed among three groups (**Figure 1D**).




Figure 2. Top 20 GO annotation terms of differentially-expressed genes for AGS1 and AGS3, according to *P* values of enriched GO terms.

Functional classification and enrichment of genes regulated by H. pylori or H. pylori CagA

Annotations of significantly differentially-expressed genes were analyzed. Functional categories of the differentially-expressed genes are shown in **Figures 2-4**.

For AGS1 and AGS3, the top 20 enriched GO terms within each major functional category are shown in **Figure 2**, according to *P*-values of enriched GO terms. The top four most enriched GO terms under “biological process” included

“cellular response to stress”, “cell death”, “death”, and “programmed cell death”. The top four most enriched GO terms under “cellular component” included “cytoplasm”, “nuclear lumen”, “nuclear part”, and “nucleoplasm”. In the molecular function category, “protein binding”, “DNA helicase activity”, “binding”, and “anion binding” were the most prominent categories.

For AGS1 and AGS4, the top 20 enriched GO terms within each major functional category are shown in **Figure 3**. The top four most

Helicobacter pylori and gastric carcinogenesis




Figure 3. Top 20 GO annotation terms of differentially-expressed genes for AGS1 and AGS4, according to P values of enriched GO terms.

Helicobacter pylori and gastric carcinogenesis




Figure 4. Top 20 GO annotation terms of differentially-expressed genes for AGS3 and AGS4, according to P values of enriched GO terms.

Helicobacter pylori and gastric carcinogenesis




Figure 5. Top 20 enriched pathways from KEGG, BioCarta, Reactome, and Panther databases of the differentially-expressed genes for AGS1 and AGS3 (A), AGS1 and AGS4 (B), AGS3 and AGS4 (C), $P < 0.05$.

enriched GO terms under “biological process” included “response to organic substance”, “cellular response to chemical stimulus”, “cell death”, and “death”. The top four most enriched GO terms under “cellular component” included “cytoplasm”, “synapse”, “plasma membrane part” and “post-synapse”. In the molecular function category, “protein binding”, “binding”, “enzyme binding”, and “ubiquitin-like protein ligase binding” were the most prominent categories.

For AGS3 and AGS4, the top 20 enriched GO terms within each major functional category are shown in **Figure 4**. The top four most enriched GO terms under “biological process” included “mitotic sister chromatid segregation”, “sister chromatid segregation”, “chromosome segregation”, and “mitotic cell cycle”. The top four most enriched GO terms under “cellular component” included “condensed nuclear chromosome, centromeric region”, “condensed nuclear chromosome kinetochore”, “spindle” and “condensed chromosome”. In the molecular function category, “identical protein binding”, “2'-5'-oligoadenylate synthetase activity”, “arachidonate 15-lipoxygenase activity”, and “protein homodimerization activity” were the most prominent categories.

Pathway analysis of genes regulated by H. pylori or H. pylori CagA

Differentially-expressed genes were mapped to a pathway database, aiming to identify biological pathways operating during gastric carcinogenesis associated with *H. pylori* infections or *H. pylori* CagA. Whole analysis results, using KEGG, BioCyc, Reactome, and Panther databases, are shown in **Figure 5**. Results of KEGG analysis are shown in [Supplementary Figure 1](#).

For AGS1 and AGS3, the top 20 enriched pathway terms are shown in **Figure 5A**. Differentially-expressed genes regulated by *H. pylori* infections were most enriched in “cell cycle”, “DNA strand elongation”, “mitotic G1-G1/S phases”, and “cellular responses to stress”. The top 20 enriched KEGG terms ([Supplementary Figure 1A](#)) showed that “cell cycle”, “DNA replication”, “metabolic pathways”, and “base excision repair” were most prominent.

For AGS1 and AGS4, the top 20 enriched pathway terms are shown in **Figure 5B**. Differentially-expressed genes regulated by CagA *H. pylori*

infections were most enriched in “MAPK signaling pathway”, “Cytokine signaling in immune system”, “cellular responses to stress”, and “development biology”. The top 20 enriched KEGG terms ([Supplementary Figure 1B](#)) showed that “MAPK signaling pathway”, “dorso-ventral axis formation”, “bladder cancer”, and “FoxO signaling pathway” were most prominent.

For AGS3 and AGS4, the top 20 enriched pathway terms are shown in **Figure 5C**. Differentially-expressed genes regulated by *H. pylori* CagA were most enriched in “cell cycle mitotic”, “cell cycle”, “M phase”, and “mitotic prometaphase”. The top 20 enriched KEGG terms ([Supplementary Figure 1C](#)) showed that “alanine, aspartate, and glutamate metabolism”, “cell cycle”, “small cell lung cancer”, and “NF-kappa B signaling pathways” were most prominent.

Experimental validation via real-time quantitative PCR

RNA-seq data were validated using real-time-PCR of eight genes. As shown in **Figure 6**, real-time quantitative PCR expression levels were generally consistent with changes identified by RNA-seq, suggesting that results of RNA-seq were reliable. IL-8, IL-33, EGFR, VEGFA, BCL2L1, TFF1, MUC13, and MUC5AC expression levels were upregulated after *H. pylori* infections. Regulation of IL-8, IL-33, BCL2L1, TFF1, MUC13, and MUC5AC genes were shown to be CagA-dependent. EGFR and VEGFA expression changes induced by *H. pylori* did not depend on CagA.

Discussion

H. pylori infections are a critical factor in the development of upper gastrointestinal diseases, including peptic ulcers, gastric cancer, and gastric mucosa-associated lymphoid-tissue (MALT) lymphoma. Eradication of *H. pylori* reduces the progression of atrophic gastritis and prevents metachronous gastric cancer [5, 19]. A recent Kyoto Global Consensus Report on *H. pylori* gastritis and the Maastricht V Consensus Report recommended *H. pylori* eradication therapy after infection [20, 21]. *H. pylori* has been hurled into the spotlight as an important pathogenic factor of gastric diseases, especially gastric carcinogenesis.

During infection, *H. pylori* CagA is delivered into gastric epithelial cells. This has been consid-




Figure 6. Validation of RNA-seq data was performed by real-time PCR. Transcript abundance changes were calculated via the FPKM method. Associated standard error bars represent relative expression levels determined by real-time PCR using the $2^{-\Delta\Delta C_t}$ method. Results represent mean standard deviation (\pm SD) of three experimental replicates. The \log_2 (fold change) values from RNA-seq and real-time PCR were consistent.

ered to be one of the most important virulence factors of this bacteria. Many studies have investigated the mechanisms of *H. pylori* and CagA. Via the type IV secretion system (TFSS), CagA can translocate into host gastric cells and regulate downstream molecular signaling pathways, affecting cell apoptosis and activate host cell survival. Kinds of molecular and axis have been reported in *H. pylori* infections or *H. pylori* CagA. It is necessary to give a whole profile of genes involved in the infection. The current study used comparative transcriptome analysis via RNA-seq screening, aiming to identify differentially-expressed genes regulated by *H. pylori* infections or *H. pylori* CagA.

Interleukin 8 (IL-8) was upregulated significantly. This is well-known as a mechanism of *H. pylori* infected gastric cells [22]. The current study used IL-8 as a positive control marker to certify the infection model were successfully published. In this study, IL-33 was upregulated. IL-33 is a cytokine that acts as a nuclear factor. It has been found to be related with development of many kinds of tumors [23]. IL-33 is expressed in gastric foveolar epithelial cells and is released upon mucosal damage. Downstream signaling of IL-33 induces the alternative activation of macrophages, which then secretes more IL-33 to create a self-sus-

taining signaling network. It promotes progression of proliferative metaplasia. In the presence of persistent injury and chronic inflammation, risks for gastric cancer development are mediated by IL-33 [24]. Further exploration should be performed concerning the mechanisms of IL-33 in *H. pylori*-induced gastric cancer.

Epidermal growth factor receptor (EGFR) is a cell surface protein of the EGF family. In tumors of epithelial origin, EGFR overexpression is at a high frequency. This may predict worse survival. EGFR upregulation has been found as the downstream of ROS generation. It is critical for gastric cancer metastasis [25, 26]. Vascular endothelial growth factor (VEGF) signaling synergizing with EGFR can promote epithelial cancer development [27]. In the current study, EGFR and VEGFA were upregulated after *H. pylori* infections, indicating EGFR and VEGFA might play a critical role in *H. pylori* related gastric cancer. Moreover, programmed cell death protein ligand 1 (PD-L1) expression has been shown to be regulated by the oncogenic driver EGFR in non-small cell lung cancer [28]. It is an important immune-checkpoint receptor of immune cells and plays a crucial role in tumor-immune-escape and immunotherapy. The term “programmed cell death” was enriched in this study. However, this study did not find that expression of PD-L1 or its receptor PD-1 to be regulated by *H. pylori*. More studies should be performed, investigating programmed cell death proteins and their ligands in the process of *H. pylori*-infected gastric carcinogenesis.

BCL-XL and MCL-1 are BCL-2 anti-apoptotic proteins. BCL2L1 (BCL-XL gene) has been reported as an anti-apoptotic target gene [29]. Its overexpression increases cell migration and invasion, facilitating tumor cells to form vasculogenic structures [30]. MCL-1 plays an important role in cervical cancer and has shown potential as a therapeutic target [31, 32]. The current study found significant upregulation of BCL2L1 and MCL-1 in *H. pylori*-infected AGS cells, indi-

cating that after *H. pylori*-infection, cells undergo tumorigenesis while DNA damage occurs. It is necessary to investigate whether BCL2L1 or MCL-1 inhibitors have a therapeutic function in *H. pylori*-infected gastric cancer.

Mucins are major ingredients of the mucus layer attached to gastric mucosa. There is a complex interaction between mucins and *H. pylori*. Secreting urease and elevating pH, *H. pylori* can liquefy surrounding mucins, enabling it to move mucins in contact with epithelial cells. Host mucins, in turn, have shown antibiotic effects fighting against *H. pylori* to control its growth and aggressiveness [33]. Some studies have shown a probable link between *H. pylori* infections, mucins, and gastric cancer, but mucins expression changes related with *H. pylori* or gastric cancer have not been clarified [34-36]. In this study, MUC13 and MUC5AC expression levels were upregulated by *H. pylori* and were CagA-dependent.

Trefoil factor 1 (TFF1) is expressed in a tissue-specific manner in surface mucous cells in gastric mucosa. Some studies have focused on the role of TFF1 in *H. pylori*-mediated gastric diseases. Serum TFF1 levels have been reported to be higher in populations with *H. pylori* infections than in those without *H. pylori* infections [37]. However, some studies have suggested that TFF1 expression is independent of *H. pylori* infections [38]. Other studies have reported that loss of TFF1 expression is involved in *H. pylori*-induced gastric carcinogenesis, indicating that TFF1 provides tumor-suppressor functions and that its expression is downregulated when *H. pylori* infections are present [39]. Recent studies have shown that TFF1 can bind to gastric mucins and help locate *H. pylori* in a discrete layer of gastric mucus, inhibiting *H. pylori* contact with epithelial cells [40]. Present results showed the upregulation of mucins and TFF1, hypothesizing that these could help the mucus layer reflect and support host fight against *H. pylori* infections. Functions of these gene expression changes should be explored more thoroughly.

According to previous studies, cell damage is serious when *H. pylori* infection MOIs of 50:1 and 100:1 was used. Some drugs could not reverse serious cell damage. The current study used a MOI of 25:1. On one hand, there are fewer experimental reports on low-concentra-

tion infections. On the other hand, the discovery of genes changes at the time of slight cell damage were expected, carrying out drug intervention targeting on these regulated genes. This could help to achieve the goal of effective treatment on *H. pylori*-mediated gastric diseases at an early stage.

Acknowledgements

This study was funded by the National Natural Science Foundation of China (Grant No. 817-00496) and Interdisciplinary Medicine Seed Fund of Peking University (BMU2017MX015).

Disclosure of conflict of interest

None.

Address correspondence to: Yanyan Shi, Peking University Third Hospital, Research Center of Clinical Epidemiology, Beijing 100191, P.R. China. E-mail: 0729xst@163.com; shiyanyan@bjmu.edu.cn

References


- [1] Ajani JA, Lee J, Sano T, Janjigian YY, Fan D and Song S. Gastric adenocarcinoma. *Nat Rev Dis Primers* 2017; 3: 17036.
- [2] Wang G, Romero-Gallo J, Benoit SL, Piazuelo MB, Dominguez RL, Morgan DR, Peek RM Jr and Maier RJ. Hydrogen metabolism in helicobacter pylori plays a role in gastric carcinogenesis through facilitating CagA translocation. *MBio* 2016; 7.
- [3] Shi Y, Liu L, Zhang T, Shen L, Liu L, Zhang J, Zhang Y, Wang X, Yang S, Lu F, Chen X and Ding S. The involvement of helicobacter pylori thioredoxin-1 in gastric carcinogenesis. *J Med Microbiol* 2013; 62: 1226-1234.
- [4] Mera RM, Bravo LE, Camargo MC, Bravo JC, Delgado AG, Romero-Gallo J, Yopez MC, Realpe JL, Schneider BG, Morgan DR, Peek RM Jr, Correa P, Wilson KT and Piazuelo MB. Dynamics of helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. *Gut* 2018; 67: 1239-1246.
- [5] Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B and Nam BH. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. *N Engl J Med* 2018; 378: 1085-1095.
- [6] Shi YY, Chen M, Zhang YX, Zhang J and Ding SG. Expression of three essential antioxidants of helicobacter pylori in clinical isolates. *J Zhejiang Univ Sci B* 2014; 15: 500-506.

Helicobacter pylori and gastric carcinogenesis

- [7] Wessler S and Backert S. A novel basolateral type IV secretion model for the CagA oncoprotein of *Helicobacter pylori*. *Microb Cell* 2017; 5: 60-62.
- [8] Waskito LA, Salama NR and Yamaoka Y. Pathogenesis of *Helicobacter pylori* infection. *Helicobacter* 2018; 23 Suppl 1: e12516.
- [9] Nejati S, Karkhah A, Darvish H, Validi M, Ebrahimpour S and Nouri HR. Influence of *Helicobacter pylori* virulence factors CagA and VacA on pathogenesis of gastrointestinal disorders. *Microb Pathog* 2018; 117: 43-48.
- [10] Hatakeyama M. *Helicobacter pylori* CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. *Cell Host Microbe* 2014; 15: 306-316.
- [11] Wada Y, Takemura K, Tummala P, Uchida K, Kitagaki K, Furukawa A, Ishige Y, Ito T, Hara Y, Suzuki T, Mimuro H, Board PG and Eishi Y. *Helicobacter pylori* induces somatic mutations in TP53 via overexpression of CHAC1 in infected gastric epithelial cells. *FEBS Open Bio* 2018; 8: 671-679.
- [12] Mimuro H, Suzuki T, Nagai S, Rieder G, Suzuki M, Nagai T, Fujita Y, Nagamatsu K, Ishijima N, Koyasu S, Haas R and Sasakawa C. *Helicobacter pylori* dampens gut epithelial self-renewal by inhibiting apoptosis, a bacterial strategy to enhance colonization of the stomach. *Cell Host Microbe* 2007; 2: 250-263.
- [13] Li FY, Weng IC, Lin CH, Kao MC, Wu MS, Chen HY and Liu FT. *Helicobacter pylori* induces intracellular galectin-8 aggregation around damaged lysosomes within gastric epithelial cells in a host O-glycan-dependent manner. *Glycobiology* 2019; 29: 151-162.
- [14] Kwon SG, Hwang JH, Park DH, Kim TW, Kang DG, Kang KH, Kim IS, Park HC, Na CS, Ha J and Kim CW. Identification of differentially expressed genes associated with litter size in Berkshire pig placenta. *PLoS One* 2016; 11: e0153311.
- [15] Liu L, Si L, Meng X and Luo L. Comparative transcriptomic analysis reveals novel genes and regulatory mechanisms of *Tetragenococcus halophilus* in response to salt stress. *J Ind Microbiol Biotechnol* 2015; 42: 601-616.
- [16] Trapnell C, Hendrickson DG, Sauvageau M, Goff L, Rinn JL and Pachter L. Differential analysis of gene regulation at transcript resolution with RNA-seq. *Nat Biotechnol* 2013; 31: 46-53.
- [17] Parreira VR, Russell K, Athanasiadou S and Prescott JF. Comparative transcriptome analysis by RNAseq of necrotic enteritis *Clostridium perfringens* during in vivo colonization and in vitro conditions. *BMC Microbiol* 2016; 16: 186.
- [18] Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-ΔΔC_T} method. *Methods* 2001; 25: 402-408.
- [19] McColl KE. Clinical practice. *Helicobacter pylori* infection. *N Engl J Med* 2010; 362: 1597-1604.
- [20] Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N and Malfertheiner P. Kyoto global consensus report on *Helicobacter pylori* gastritis. *Gut* 2015; 64: 1353-1367.
- [21] Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K and El-Omar EM. Management of *Helicobacter pylori* infection-the Maastricht V/Florence consensus report. *Gut* 2017; 66: 6-30.
- [22] Panpetch W, Spinler JK, Versalovic J and Tumwasorn S. Characterization of *Lactobacillus salivarius* strains B37 and B60 capable of inhibiting IL-8 production in *Helicobacter pylori*-stimulated gastric epithelial cells. *BMC Microbiol* 2016; 16: 242.
- [23] Larsen KM, Minaya MK, Vaish V and Pena MMO. The role of IL-33/ST2 pathway in tumorigenesis. *Int J Mol Sci* 2018; 19.
- [24] Meyer AR and Goldenring JR. Injury, repair, inflammation and metaplasia in the stomach. *J Physiol* 2018; 596: 3861-3867.
- [25] Du S, Miao J, Zhu Z, Xu E, Shi L, Ai S, Wang F, Kang X, Chen H, Lu X, Guan W and Xia X. NADPH oxidase 4 regulates anoikis resistance of gastric cancer cells through the generation of reactive oxygen species and the induction of EGFR. *Cell Death Dis* 2018; 9: 948.
- [26] Ooft ML, Braunius WW, Heus P, Stegeman I, van Diest PJ, Grolman W, Zuur CI and Willems SM. Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis. *Biomark Med* 2015; 9: 997-1010.
- [27] Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P and Sibilina M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. *Cell* 2010; 140: 268-279.
- [28] Bassanelli M, Sioletic S, Martini M, Giacinti S, Viterbo A, Staddon A, Liberati F and Ceribelli A. Heterogeneity of PD-L1 expression and relationship with biology of NSCLC. *Anticancer Res* 2018; 38: 3789-3796.
- [29] Greenhough A, Bagley C, Heesom KJ, Gurevich DB, Gay D, Bond M, Collard TJ, Paraskeva C, Martin P, Sansom OJ, Malik K and Williams AC.

- Cancer cell adaptation to hypoxia involves a HIF-GPRC5A-YAP axis. *EMBO Mol Med* 2018; 10.
- [30] Trisciuglio D, Tupone MG, Desideri M, Di Martile M, Gabellini C, Buglioni S, Pallocca M, Alessandrini G, D'Aguanno S and Del Bufalo D. BCL-XL overexpression promotes tumor progression-associated properties. *Cell Death Dis* 2017; 8: 3216.
- [31] Zhang T, Zhao C, Luo L, Zhao H, Cheng J and Xu F. The expression of Mcl-1 in human cervical cancer and its clinical significance. *Med Oncol* 2012; 29: 1985-1991.
- [32] Lian BSX, Yek AEH, Shuvas H, Abdul Rahman SF, Muniandy K and Mohana-Kumaran N. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines. *BMC Res Notes* 2018; 11: 197.
- [33] Niv Y. *Helicobacter pylori* and gastric mucin expression: a systematic review and meta-analysis. *World J Gastroenterol* 2015; 21: 9430-9436.
- [34] Shi D, Qiu XM and Bao YF. Effects of *Helicobacter pylori* infection on MUC5AC protein expression in gastric cancer. *Future Oncol* 2013; 9: 115-120.
- [35] Kang HM, Kim N, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Lee HS, Jung HC and Song IS. Effects of *Helicobacter pylori* infection on gastric mucin expression. *J Clin Gastroenterol* 2008; 42: 29-35.
- [36] Zhang X, Shi D, Liu YP, Chen WJ and Wu D. Effects of the *Helicobacter pylori* virulence factor CagA and ammonium Ion on mucins in AGS cells. *Yonsei Med J* 2018; 59: 633-642.
- [37] Aikou S, Ohmoto Y, Gunji T, Matsuhashi N, Ohtsu H, Miura H, Kubota K, Yamagata Y, Seto Y, Nakajima A, Goldenring JR, Kaminishi M and Nomura S. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. *Gastroenterology* 2011; 141: 837-845, e831-837.
- [38] Alvarez MC, Fernandes J, Michel V, Touati E and Ribeiro ML. Effect of *Helicobacter pylori* infection on GATA-5 and TFF1 regulation, comparison between pediatric and adult patients. *Dig Dis Sci* 2018; 63: 2889-2897.
- [39] Soutto M, Chen Z, Katsha AM, Romero-Gallo J, Krishna US, Piazuolo MB, Washington MK, Peek RM Jr, Belkhir A and El-Rifai WM. Trefoil factor 1 expression suppresses *Helicobacter pylori*-induced inflammation in gastric carcinogenesis. *Cancer* 2015; 121: 4348-4358.
- [40] Dunne C, Naughton J, Duggan G, Loughrey C, Kilcoyne M, Joshi L, Carrington S, Earley H, Backert S, Robbe Masselot C, May FEB and Clyne M. Binding of *Helicobacter pylori* to human gastric Mucins correlates with binding of TFF1. *Microorganisms* 2018; 6.

Helicobacter pylori and gastric carcinogenesis



Supplementary Figure 1. Top 20 enriched KEGGpathways of differentially-expressed genes for AGS1 and AGS3 (A), AGS1 and AGS4 (B), AGS3 and AGS4 (C), $P < 0.05$.